Quick Answer
Alzamend Neuro, Inc. reported R&D Expense of $1.41 million for fiscal year 2025.
Alzamend Neuro, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.41M | -78.1% |
| 2024 | $6.46M | -13.3% |
| 2023 | $7.45M | +43.2% |
| 2022 | $5.20M | +296.8% |
| 2021 | $1.31M | +22.6% |
| 2020 | $1.07M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | $176.3K | -43.3% | -89.9% |
| July 31, 2025 | $1.74M | +742.7% | +289.4% |
| January 31, 2025 | $447.1K | -76.6% | +43.7% |
| October 31, 2024 | $311.1K | -84.4% | +50.6% |
| July 31, 2024 | $206.6K | -91.3% | -89.2% |
| January 31, 2024 | $1.91M | -33.9% | -4.4% |
| October 31, 2023 | $2.00M | +30.3% | -15.6% |
| July 31, 2023 | $2.37M | +72.0% | -18.1% |
- Alzamend Neuro, Inc. showed a decrease of -78.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Alzamend Neuro, Inc.’s r&d expense has grown by 32.3% (from $1.07 million to $1.41 million).
- The most recent figure is from Alzamend Neuro, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: